曲伏前列素滴眼液降眼压疗效的临床观察

A CLINICAL STUDY ON THE OCULAR HYPOTENSIVE EFFECT OF TRAVOPROST EYE DROPS (TRAVATAN)

目的:评价苏为坦(0.004%曲伏前列素滴眼液)降眼压的效果及安全性。方法:对16例(31眼)使用其它降眼压药物眼压控制不佳或无法耐受其它降眼压药物的开角型青光眼和高眼压症患者单独应用苏为坦,每晚1次每次1滴,共随访12周。用药后2周、4周、8周、12周在同一时段复查眼压一次,用药12周后在同一天的8点、11点、14点、16点分别检查眼压。并随访视力、视野及眼部和全身不良反应。结果:用药前眼压为24.67±2.63mmHg,4次随访眼压分别为19.54±4.18mmHg、18.45±3.23mmHg、18.67±3.01mmHg、16.23±2.91mmHg,眼压下降率最大为35.1%,用药后眼压与基础值比较差异有统计学意义(P<0.01)。治疗12周时不同时间点眼压下降值比较差异无统计学意义(P>0.05)。用药后部分病例出现轻到中部的结膜充血、眶周色素沉着等。未发现明显的其它眼部改变和全身副作用。结论:苏为坦能显著降低原发性开角型青光眼和高眼压症患者的眼压,而且安全稳定、具有良好的耐受性和依从性。

Objective ：To evaluate the effect and safety of travoprost in reducing IOP.Methods：31 eyes of 16 primary open angleglaucoma（POAG）/ocular hypertension（OHT） patients with travoprost one drop once daily were studied.The follow up duration was 12 weeks.The observed signs included lOP （measured at the same time on the 2nd, forth,eighth,twelfth week,）,visual acuity,visual field and complications.Results：The lOP was 24.67±2.63mmHg before using travoprost.2,4,8,12 weeks after treatment,the lOP were 19.54±4.18mmHg,18.45 ±3.23mmHg,and 18.67±3.01mmHg,16.23±2.91mmHg respectively.Travoprost reduced lOP significantly （P〈0.01）,the maximal reducing rate was 35.1%.After 12 weeks,lOP reductions had no obvious difference when measured at different time on the same day （P〉0.05）.Some cases had mild to moderate ocular hyperemia and pigmentation on preorbit.There had no other serious ocular or systematic complications.Conclusion：Travoprost reduced lOP significantly in POAG/O- HT,and was safe and well tolerated.